Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

93
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
93
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

420
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
420
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

80
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Tissue Transplantation01:24

Tissue Transplantation

1.4K
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
1.4K
Gene Therapy00:59

Gene Therapy

22.0K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
22.0K
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

12.4K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
12.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surface carbohydrate recognition determinants for phagocytosis.

Immunology today·2014
Same author

Physiological role of autoantibodies.

Immunology today·2014
Same author

Cytological studies in the Musae; meiosis in some triploid clones.

Genetics·2010
Same author

Cytological studies in the Musae; meiosis in some diploid clones.

Genetics·2010
Same author

Cytological studies in the Musae; meiosis in some seedling clones.

Genetics·2010
Same author

The Venetian turpentine mounting medium.

Stain technology·2010

Related Experiment Video

Updated: Apr 22, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.6K

Is controversy about 'transfer factor therapy' nearing an end?

G B Wilson1, H Hugh Fudenberg

  • 1Department of Basic and Clinical Immunology and Microbiology, Medical University of South Carolina, Charleston, SC 29425, USA.

Immunology Today
|October 8, 2014
PubMed
Summary

Dialysable leukocyte extracts, also known as transfer factor, show unmistakable therapeutic value in specific patient groups. Recent trials confirm their efficacy in certain circumstances, validating earlier findings.

More Related Videos

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

13.8K
Preparing T Cell Growth Factor from Rat Splenocytes
18:27

Preparing T Cell Growth Factor from Rat Splenocytes

Published on: October 31, 2007

12.2K

Related Experiment Videos

Last Updated: Apr 22, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.6K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

13.8K
Preparing T Cell Growth Factor from Rat Splenocytes
18:27

Preparing T Cell Growth Factor from Rat Splenocytes

Published on: October 31, 2007

12.2K

Area of Science:

  • Immunology
  • Cellular Therapy

Background:

  • Transfer factor was first described nearly 30 years ago.
  • Dialysable leukocyte extracts (DLEs) are derived from leukocytes.

Purpose of the Study:

  • To examine the therapeutic value of DLEs in adequately designed trials.
  • To provide evidence for the efficacy of DLEs in specific clinical scenarios.

Main Methods:

  • Conducting adequately designed clinical trials.
  • Evaluating patient outcomes in specific circumstances.

Main Results:

  • Unmistakable evidence of efficacy was found.
  • DLEs demonstrated therapeutic value in certain patients.

Conclusions:

  • DLEs possess significant therapeutic potential.
  • Further research and application in specific patient populations are warranted.